Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

corteva agriscience australia pty ltd - chlorpyrifos-methyl; liquid hydrocarbon - emulsifiable concentrate - chlorpyrifos-methyl organophosphorus active 500.0 g/l; liquid hydrocarbon solvent other 495.0 g/l - insecticide - grain storage area - see label | lupin - stored | stored cereal grain-label for exceptions | bins | building surface | machinery - confused flour beetle | granary weevil | lesser grain borer - susceptible strains | lesser grain borer-multi resistant strns | maize weevil | rice weevil | rust-red flour beetle | sawtoothed grain beetle | tropical warehouse moth | warehouse beetle

États-Unis - anglais - NLM (National Library of Medicine)

misemer pharmaceutical - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), pantothenic acid (unii: 19f -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - fosaprepitant dimeglumine, quantity: 257.6 mg (equivalent: fosaprepitant, qty 150 mg) - injection, powder for - excipient ingredients: disodium edetate; sodium hydroxide; hydrochloric acid; polysorbate 80; lactose - emend iv, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: - highly emetogenic cancer chemotherapy (see dosage and administration); - moderately emetogenic cancer chemotherapy (see dosage and administration).

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fexofenadine hydrochloride 6 mg/ml; fexofenadine hydrochloride 6 mg/ml - oral suspension - 6 mg/ml - active: fexofenadine hydrochloride 6 mg/ml excipient: butyl hydroxybenzoate dibasic sodium phosphate heptahydrate disodium edetate monobasic sodium phosphate monohydrate poloxamer propyl hydroxybenzoate propylene glycol purified water raspberry flavour f-9950 pfc sucrose titanium dioxide xanthan gum xylitol active: fexofenadine hydrochloride 6 mg/ml excipient: dibasic sodium phosphate heptahydrate disodium edetate monobasic sodium phosphate monohydrate poloxamer potassium sorbate propylene glycol purified water raspberry flavour f-9950 pfc sucrose titanium dioxide xanthan gum xylitol - relief of symptoms associated with seasonal allergic rhinitis and allergic rhinitis in adults and children from 2 years of age.

Singapour - anglais - HSA (Health Sciences Authority)

abbvie pte. ltd. - lopinavir; ritonavir - tablet, film coated - 100mg - lopinavir 100mg; ritonavir 25mg

Singapour - anglais - HSA (Health Sciences Authority)

abbvie pte. ltd. - lopinavir; ritonavir - tablet, film coated - 200.0mg - lopinavir 200.0mg; ritonavir 50.0mg

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - fexofenadine hydrochloride, quantity: 6 mg/ml - oral liquid, suspension - excipient ingredients: xanthan gum; butyl hydroxybenzoate; propyl hydroxybenzoate; titanium dioxide; disodium edetate; purified water; monobasic sodium phosphate monohydrate; poloxamer; xylitol; propylene glycol; dibasic sodium phosphate heptahydrate; sucrose; flavour - relief of symptoms associated with seasonal allergic rhinitis and allergic rhinitis in adults and children from 2 years of age. relief of symptoms associated with urticaria in adults and children from 6 months of age.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: hyprolose; povidone; propylene glycol; purified talc; sodium starch glycollate type a; hypromellose; sodium starch glycollate type b; maize starch; magnesium stearate; colloidal anhydrous silica; poloxamer; glucose; titanium dioxide - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: povidone; sodium starch glycollate type a; glucose; purified talc; hypromellose; maize starch; sodium starch glycollate type b; propylene glycol; hyprolose; poloxamer; titanium dioxide; colloidal anhydrous silica; magnesium stearate - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible microorganisms: acute pharyngitis. acute tonsillitis, impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - fexofenadine hydrochloride, quantity: 30 mg - tablet, film coated - excipient ingredients: titanium dioxide; pregelatinised maize starch; hypromellose; macrogol 400; colloidal anhydrous silica; magnesium stearate; povidone; microcrystalline cellulose; croscarmellose sodium; iron oxide red; iron oxide yellow - relief of symptoms associated with seasonal allergic rhinitis, allergic rhinitis or urticaria in adults and children from 6 years of age.